Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cancer

Call for papers: The Advances of CAR Immunotherapy within Oncology Clinics

New Content ItemBMC Cancer and BMC Biotechnology are delighted to announce the launch of a new cross-journal thematic series focused on the emerging field of Chimeric Antigen Receptor (CAR) Immunotherapy, which will review and feature the role of synthetic biology and gene engineering in CAR Immunotherapy, but also the advances of CAR Immunotherapy within oncology clinics.

Featured blog: Systematic reviews made simple

New Content ItemBMC Cancer recently published a systematic review of previous systematic reviews with statistical analyses and meta-analyses, regarding the effects of exercise on cancer-related-fatigue in adult cancer patients and survivors. In this blog, Prof. George Kelley, Director of the Meta-Analytic Research Group at West Virginia University, discusses more about his approach and the associated challenges.

Featured video: Microparticles, breast cancer's secret weapon?

Read the article

Articles

  1. Content type: Database

      |  

    Authors: S. R. Saifuddin, W. Devlies, A. Santaolalla, F. Cahill, G. George, D. Enting, S. Rudman, P. Cathcart, B. Challacombe, P. Dasgupta, C. Galustian, A. Chandra, S. Chowdhury, C. Gillett and M. Van Hemelrijck

View all articles
View all articles

Aims and scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

Editor

Consulting Editors

Manami Inoue, Consulting Editor

Manami Inoue, MD, PhD, is the Division Chief at the Center for Public Health Sciences, National Cancer Center, Japan. She joined the editorial board of BMC Cancer in 2011 as Section Editor. She has been serving as Consulting Editor since 2017.

 

 

Latest Tweets

Advertisement